This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ERYP ERYTECH Pharma (ERYP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About ERYTECH Pharma Stock (NASDAQ:ERYP) 30 days 90 days 365 days Advanced Chart Get ERYTECH Pharma alerts:Sign Up Key Stats Today's Range$3.10▼$3.1050-Day Range$4.19▼$5.0852-Week Range$0.30▼$1.47VolumeN/AAverage Volume93,510 shsMarket Capitalization$105.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Read More… Receive ERYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ERYP Stock News HeadlinesPhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketFebruary 21, 2024 | finanznachrichten.deRoyalty Pharma PLC Class A RPRXJanuary 19, 2024 | morningstar.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 4, 2025 | Brownstone Research (Ad)Erytech Pharma S.A.: Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXMJune 28, 2023 | finanznachrichten.dePhaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXMJune 28, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - June 26, 2023June 27, 2023 | finance.yahoo.comERYTECH and PHERECYDES announce merger and name change to PHAXIAM TherapeuticsJune 26, 2023 | finance.yahoo.comERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023June 23, 2023 | finance.yahoo.comSee More Headlines ERYP Stock Analysis - Frequently Asked Questions When did ERYTECH Pharma IPO? ERYTECH Pharma (ERYP) raised $125 million in an initial public offering on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager. What other stocks do shareholders of ERYTECH Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ERYTECH Pharma investors own include Ardelyx (ARDX), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN), Pfizer (PFE), Sesen Bio (SESN), Nymox Pharmaceutical (NYMX) and ObsEva (OBSV). Company Calendar Today5/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ERYP CIK1624422 Webwww.erytech.com Phone(347) 874-4438Fax33-4-78-75-56-29Employees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.32 Current Ratio3.65 Quick Ratio3.65 Sales & Book Value Annual Sales$32.66 million Price / Sales3.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book3.88Miscellaneous Outstanding Shares34,120,000Free Float33,458,000Market Cap$105.77 million OptionableNot Optionable Beta2.69 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:ERYP) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share ERYTECH Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.